GlassScriptPhysician profile
Kenneth C Walters
NPI 1366679458
$80,525.98
in general payments reported to CMS, 2019-2025
61 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,403 · 2020: $11K · 2021: $9,557 · 2022: $18K · 2023: $18K · 2024: $8,531 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Education: $7,089 · Food and Beverage: $5,047 · Travel and Lodging: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,225.00 |
| Education | $7,089.33 |
| Food and Beverage | $5,046.73 |
| Travel and Lodging | $357.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $67,063.81 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Intuitive Surgical, INC. | $7,095.52 | 2023-2025 | Da Vinci Surgical System, Ion |
| Glaxosmithkline, LLC. | $1,015.01 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $783.59 | 2019-2025 | Ofev, Stiolto Respimat |
| Actelion Pharmaceuticals US, INC. | $331.28 | 2019-2024 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $322.83 | 2019-2025 | Zerbaxa, Recarbrio, Keytruda |
| Insmed, INC. | $309.45 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $307.30 | 2019-2025 | Tyvaso, Tyvaso |
| Pinnacle Biologics, INC | $300.00 | 2022 | |
| Electromed, INC. | $265.07 | 2019-2025 | Smartvest |
| Genzyme Corporation | $247.96 | 2021-2025 | |
| Grifols USA, LLC | $236.35 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $223.25 | 2020-2025 | Glassia, Cuvitru, Hyqvia |
| Genentech USA, INC. | $122.64 | 2019-2023 | Xolair |
| Axsome Therapeutics, INC. | $119.71 | 2025 | Sunosi |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Walters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.